CA2473679A1 - Dna dosage forms - Google Patents

Dna dosage forms Download PDF

Info

Publication number
CA2473679A1
CA2473679A1 CA002473679A CA2473679A CA2473679A1 CA 2473679 A1 CA2473679 A1 CA 2473679A1 CA 002473679 A CA002473679 A CA 002473679A CA 2473679 A CA2473679 A CA 2473679A CA 2473679 A1 CA2473679 A1 CA 2473679A1
Authority
CA
Canada
Prior art keywords
dna
pharmaceutical agent
delivery device
agent delivery
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002473679A
Other languages
English (en)
French (fr)
Inventor
Ian Richard Catchpole
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2473679A1 publication Critical patent/CA2473679A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002473679A 2002-01-25 2003-01-23 Dna dosage forms Abandoned CA2473679A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0201736.6 2002-01-25
GBGB0201736.6A GB0201736D0 (en) 2002-01-25 2002-01-25 DNA dosage forms
PCT/GB2003/000282 WO2003061636A2 (en) 2002-01-25 2003-01-23 Dna dosage forms

Publications (1)

Publication Number Publication Date
CA2473679A1 true CA2473679A1 (en) 2003-07-31

Family

ID=9929749

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002473679A Abandoned CA2473679A1 (en) 2002-01-25 2003-01-23 Dna dosage forms

Country Status (10)

Country Link
US (1) US20050080028A1 (https=)
EP (1) EP1467720B1 (https=)
JP (1) JP2005526016A (https=)
AT (1) ATE427105T1 (https=)
AU (1) AU2003202685A1 (https=)
CA (1) CA2473679A1 (https=)
DE (1) DE60326930D1 (https=)
ES (1) ES2322572T3 (https=)
GB (1) GB0201736D0 (https=)
WO (1) WO2003061636A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
WO2005020912A2 (en) 2003-08-25 2005-03-10 3M Innovative Properties Company Delivery of immune response modifier compounds
BRPI0415850A (pt) * 2003-10-23 2007-01-02 Alza Corp composição de dna estabilizado para o revestimento de micro projeções
US7591806B2 (en) * 2004-05-18 2009-09-22 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
EP2272430A1 (en) 2004-08-16 2011-01-12 Functional Microstructures Limited Method of producing a microneedle or microimplant
US8048017B2 (en) * 2005-05-18 2011-11-01 Bai Xu High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
US8043250B2 (en) * 2005-05-18 2011-10-25 Nanomed Devices, Inc. High-aspect-ratio microdevices and methods for transdermal delivery and sampling of active substances
CN101227940A (zh) * 2005-07-25 2008-07-23 纳米技术维多利亚有限公司 微阵列装置
CA2629193C (en) 2005-11-18 2016-03-29 3M Innovative Properties Company Coatable compositions, coatings derived therefrom and microarrays having such coatings
US10525246B2 (en) 2006-12-22 2020-01-07 Nanomed Skincare, Inc. Microdevice and method for transdermal delivery and sampling of active substances
US20080214987A1 (en) * 2006-12-22 2008-09-04 Nanomed Devices, Inc. Microdevice And Method For Transdermal Delivery And Sampling Of Active Substances
US8512679B2 (en) 2011-03-04 2013-08-20 Elwha Llc Glassy compositions
CN103717249B (zh) 2011-06-15 2017-03-22 克洛恩泰克制药股份公司 注射针和装置
KR101314091B1 (ko) * 2011-07-26 2013-10-04 연세대학교 산학협력단 치료 부위내 경피 유전자 전달을 위한 일렉트로 마이크로니들 집적체 및 이의 제조방법
JP2013052202A (ja) * 2011-09-01 2013-03-21 Kosumedei Seiyaku Kk Ｄｎａワクチンマイクロニードル
US10064960B2 (en) * 2011-11-25 2018-09-04 Danmarks Tekniske Universitet Formulation of solid nano-sized particles in a gel-forming system

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE235558T1 (de) * 1989-06-26 2003-04-15 Powderject Vaccines Inc Transformation von tierischen somatischen zellen mittels partikeln
US5697901A (en) * 1989-12-14 1997-12-16 Elof Eriksson Gene delivery by microneedle injection
JPH08510639A (ja) * 1993-04-19 1996-11-12 メディソーブ・テクノロジーズ・インターナショナル・リミテッド・パートナーシップ 細胞取込みと遺伝子発現の促進と標的化をもたらす接合体と核酸のカプセル化
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
AU705889B2 (en) * 1993-08-26 1999-06-03 Regents Of The University Of California, The Method, compositions and devices for administration of naked polynucleotides which encode antigens and immunostimulatory peptides
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
ES2208687T3 (es) * 1994-08-04 2004-06-16 Elan Drug Delivery Limited Sistema de administracion de sustancias solidas para la liberacion controlada de moleculas incorporadas en tales sustancias y procedimientos para la fabricacion de tales sistemas.
EP0906110B1 (en) * 1996-04-26 2004-12-22 Merck & Co., Inc. Dna vaccine formulations
EP1100579B1 (en) * 1998-07-13 2015-09-02 Inovio Pharmaceuticals, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6713291B2 (en) * 1999-01-28 2004-03-30 Alan D. King Electrodes coated with treating agent and uses thereof
EP1163024B1 (en) * 1999-01-28 2003-12-17 Cyto Pulse Sciences, Inc. Delivery of macromolecules into cells
US6743211B1 (en) * 1999-11-23 2004-06-01 Georgia Tech Research Corporation Devices and methods for enhanced microneedle penetration of biological barriers
US6835184B1 (en) * 1999-09-24 2004-12-28 Becton, Dickinson And Company Method and device for abrading skin
US20020002136A1 (en) * 2000-06-28 2002-01-03 Hebert Rolland F. Salts of glutathione
EP1299087A1 (en) * 2000-07-07 2003-04-09 Corixa Corporation Microspheres and adjuvants for dna vaccine delivery
GB0017999D0 (en) * 2000-07-21 2000-09-13 Smithkline Beecham Biolog Novel device
NZ529029A (en) * 2001-04-20 2005-07-29 Alza Corp Microprojection array having a beneficial agent containing coating

Also Published As

Publication number Publication date
EP1467720A2 (en) 2004-10-20
ATE427105T1 (de) 2009-04-15
US20050080028A1 (en) 2005-04-14
DE60326930D1 (de) 2009-05-14
ES2322572T3 (es) 2009-06-23
EP1467720B1 (en) 2009-04-01
WO2003061636A3 (en) 2003-11-27
GB0201736D0 (en) 2002-03-13
AU2003202685A1 (en) 2003-09-02
WO2003061636A2 (en) 2003-07-31
JP2005526016A (ja) 2005-09-02

Similar Documents

Publication Publication Date Title
EP1301238B1 (en) Needles coated with vaccine
EP1467720B1 (en) Dna dosage forms
WO2005051456A2 (en) Composition and apparatus for transdermal delivery
JP2018502927A (ja) マイクロニードルワクチンパッチ用ミョウバン含有コーティング製剤
KR20070057954A (ko) 알룸-애주번트가 있는 면역 활성제의 안정화
US20080095854A1 (en) Dna dosage forms
EP1528914B1 (en) Antigenic compositions
EP1592443A1 (en) Improved anthrax vaccines and delivery methods
WO2000043058A1 (en) Method of enhancing needleless transdermal powdered drug delivery
US20070196490A1 (en) Method of enhancing needleless transdermal powered drug delivery

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued